CN103667281A - Molecular marker miR-301a for prostatic cancer and application of molecular marker miR-301a - Google Patents
Molecular marker miR-301a for prostatic cancer and application of molecular marker miR-301a Download PDFInfo
- Publication number
- CN103667281A CN103667281A CN201210314263.0A CN201210314263A CN103667281A CN 103667281 A CN103667281 A CN 103667281A CN 201210314263 A CN201210314263 A CN 201210314263A CN 103667281 A CN103667281 A CN 103667281A
- Authority
- CN
- China
- Prior art keywords
- prostate cancer
- mir
- molecular marker
- diagnostic kit
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 91
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 90
- 108091029203 miR-301 stem-loop Proteins 0.000 title claims abstract description 41
- 108091026505 miR-301a stem-loop Proteins 0.000 title claims abstract description 41
- 239000003147 molecular marker Substances 0.000 title claims abstract description 33
- 210000002966 serum Anatomy 0.000 claims abstract description 31
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 239000012807 PCR reagent Substances 0.000 claims description 10
- 238000003753 real-time PCR Methods 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 5
- 238000002123 RNA extraction Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 238000012544 monitoring process Methods 0.000 abstract description 7
- 238000004393 prognosis Methods 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 239000002679 microRNA Substances 0.000 description 22
- 108091070501 miRNA Proteins 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011337 individualized treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000013456 study Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091027766 Mir-143 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 description 1
- 108091062140 Mir-223 Proteins 0.000 description 1
- 108091093189 Mir-375 Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000005224 forefinger Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005184 men's health Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 108091064157 miR-106a stem-loop Proteins 0.000 description 1
- 108091070946 miR-128 stem-loop Proteins 0.000 description 1
- 108091027034 miR-148a stem-loop Proteins 0.000 description 1
- 108091037426 miR-152 stem-loop Proteins 0.000 description 1
- 108091025686 miR-199a stem-loop Proteins 0.000 description 1
- 108091083769 miR-199a-1 stem-loop Proteins 0.000 description 1
- 108091047470 miR-199a-2 stem-loop Proteins 0.000 description 1
- 108091048350 miR-199a-3 stem-loop Proteins 0.000 description 1
- 108091056793 miR-199a-4 stem-loop Proteins 0.000 description 1
- 108091074450 miR-200c stem-loop Proteins 0.000 description 1
- 108091049679 miR-20a stem-loop Proteins 0.000 description 1
- 108091040176 miR-218 stem-loop Proteins 0.000 description 1
- -1 miR-27a Proteins 0.000 description 1
- 108091063344 miR-30b stem-loop Proteins 0.000 description 1
- 108091030938 miR-424 stem-loop Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a novel molecular marker miR-301a for the diagnosis of prostatic cancer and an application of the molecular marker to the preparation of a diagnostic kit for diagnosing prostatic cancer. The content of miR-301a in the blood serum of a prostatic cancer patient is higher than that in the blood serum of a normal person, while the content of the miR-301a in the blood serum of the prostatic cancer patient is returned to the normal level after the patient undergoes an operation. The invention also provides the diagnostic kit for diagnosing prostatic cancer. When used for diagnosing prostatic cancer, the molecular marker and the diagnostic kit with the molecular marker are simple in operation, convenient to obtain materials, safe and noninvasive and have the characteristics of high specificity and sensitivity and easiness for large-area screening. The molecular marker is particularly suitable for reagents applied to the fields such as high risk group screening of prostatic cancer, prostatic cancer authentication, prostatic cancer treatment condition monitoring, prostatic cancer guiding pharmacy monitoring, prostatic cancer prognosis monitoring and the like.
Description
Technical field
The present invention relates to biological technical field, be specifically related to a kind of prostate cancer molecular marker miR-301a and the application in preparing diagnosing prostate cancer reagent thereof, relate in particular to prostate cancer molecular marker miR-301a in prostate cancer high risk population's screening, the monitoring of the evaluation of prostate cancer, prostate cancer therapy situation, the application in reagent for the field such as the monitoring of prostate cancer direction of medication usage and prostate cancer Prognosis scoveillance.
Background technology
MicroRNA(miRNA) be the non-coding strand microRNA molecules that length that a class is encoded by native gene is about 22 Nucleotide, it has multiple important regulating effect in cell.Each miRNA can have a plurality of target genes, and several miRNA also can regulate same gene.The regulating networks of this complexity both can regulate and control by a miRNA expression of a plurality of genes, also can carry out by the combination of several miRNA the expression of certain gene of finely regulating.By inference, miRNA is regulating the gene of one of trichotomy.MicroRNA plays an increasingly important role at aspects such as disease incidence Mechanism Study, early diagnosis, individualized treatment and prognosis because its feature such as conservative property, Space-time speciality, stability and tissue specificity highly makes it be better than the other biological marks such as protein, DNA fragmentation.
Patients with prostate cancer is mainly elderly men, generally at 50 years old with sequela, 95% betides 60 years old above elderly men, incidence increases with age growth constantly.In the U.S., the sickness rate of prostate cancer has surpassed lung cancer, becomes the tumour of first harm men's health.The sickness rate of Asia prostate cancers such as China are well below American-European countries, but present in recent years ascendant trend.Prostate cancer is early stage many without any symptom, even uncomfortable to some extent, is also not enough to cause patient's attention.When tumour increases compressing urethra, often obscure mutually with hyperplasia of prostate again.First patient in China approximately 80% finds distant metastasis focus, then just finds prostate cancer.Now, pathology has belonged to late period, prognosis mala.
At present, the clinical diagnosis mode of prostate cancer mainly contains following several: digital rectal examination, serum PSA (PSA) detection, the detection of endorectal ultrasonography ripple, living tissue pathologic finding etc.Digital rectal examination is method the simplest, most economical practicality, is mainly the forefinger touch prostate gland by doctor, in order to find a lot of asymptomatic patients with prostate cancer, likely obtains the chance of early diagnosis and radical cure.But aforesaid method all has some limitations.As the limitation of digital rectal examination is:, when patient's prostate gland lump is little, easily fail to pinpoint a disease in diagnosis (1); (2) the patient's prostate cancer enlargement having is not obvious, but has belonged to late period, is difficult for radical cure; (3) patient is had to certain harm that do not accommodate, when patient's rectum has illness, can not use this detection; (4) when doctors experience deficiency, fail to pinpoint a disease in diagnosis or mistaken diagnosis possibility.PSA in blood not high (not higher than 4ng/ml) under normal circumstances, when in prostate cancer and other prostatosis disease states, PSA raises, become the most responsive knurl mark of current examination prostate cancer, but also there is certain limitation in it: (1) need to get blood examination and survey, and patient is had to certain damage; (2) PSA increases and is also common in non-prostate cancer disease, as prostatitis, prostatomegaly etc., is therefore difficult for making a definite diagnosis; (3) PSA increases while making a definite diagnosis prostate cancer, and often patient has belonged to the intermediary and later stages, does not reach the object of early diagnosis.Prostate gland ultrasound examination directly perceived, not damaged easy and simple to handle, locates and qualitative sign judge the character of pathology by showing that size, number, position, density, edge, form, the form that has or not calcification and calcification, size, number, substep and halo around, the skin change etc. of lump provide: its limitation is: easily fail to pinpoint a disease in diagnosis the little cancer kitchen range of compactness (1); (2) sometimes can not provide clear and definite etiologic diagnosis; (3) thus because of its can not show the internal structure of tumour and surrounding tissue diagnostic accordance rate very low; (4) the good Malignant mass of real property that some is lacked to typical sign has higher misdiagnosis rate.Living tissue pathologic finding because it is traumatic, complicacy can not be as the means of primary dcreening operation, but its gold standard that to be prostate cancer make a definite diagnosis, general and additive method technical battery use.
Research in recent years shows, prostate cancer is closely related with miRNA, and they may participate in generation, development and the transfer of tumour, so may have corresponding effect to the detection of the pathogenesis of tumour, early diagnosis, individualized treatment, transfer and prognosis etc.More and the effect of the miRNA kind relevant to prostate cancer differs, and there are some researches show that the miRNA raising comprises miR-375 in patients with prostate cancer, miR-148a, miR-200c, miR-106a, mir-128, miR-218, miR-20a, and miR-30b etc.; The miRNA lowering comprises miR-143, miR-145, miR-199a-5p, miR-223, miR-27a, miR-152 and miR-424 etc.Although carried out some researchs in this field, all there is deficiency the accuracy of existing miRNA mark, susceptibility aspect, in clinical and research, still there is the demand of finding more accurate and sensitive prostate cancer miRNA mark.
Summary of the invention
In order to overcome above-mentioned the deficiencies in the prior art, the invention provides a kind of new prostate cancer molecular marker relevant to prostate cancer, and the application of this molecular marker in preparing diagnosing prostate cancer reagent is provided.
The molecular marker of this prostate cancer is miR-301a, and its nucleotides sequence is classified 5 '-GCUCUGACUUUAUUGCACUACU-3 ' (SEQ ID NO:1) as.In research process, contriver finds, the content of miR-301a in serum of patients with prostate cancer is higher than the content in normal human serum, and receiving after operation when patients with prostate cancer, the content of the miR-301a in its serum just falls back to the normal level the same with content in normal human serum.As can be seen here, patient exists close dependency at the miR-301a increasing during one's sickness and the tumour of prostate cancer.On the basis of above-mentioned discovery, the invention provides a kind of prostate cancer molecular marker, and the application of this molecular marker in preparing diagnosing prostate cancer reagent.
The present invention for the technical scheme that solves its technical problem and adopt is:
A prostate cancer molecular marker miR-301a, its nucleotides sequence is classified the sequence shown in SEQ ID NO.1 as, is 5 '-GCUCUGACUUUAUUGCA CUACU-3 '.
The application of described prostate cancer molecular marker miR-301a in preparing diagnosing prostate cancer reagent is, described diagnosing prostate cancer reagent passes through to detect the content of miR-301a in subject's serum, and this miR-301a content is compared diagnosing prostate cancer with normal level miR-301a content.
In described subject's serum, the content of miR-301a detects by quantifying PCR method.
Described prostate cancer molecular marker miR-301a is for the preparation of the diagnostic kit of diagnosing prostate cancer.
The diagnostic kit of described diagnosing prostate cancer comprises:
(1) serum total RNA extraction reagent,
(2) RNA adds polyA reagent,
(3) RT-PCR reagent,
(4) quantitative PCR reagent;
Wherein said quantitative PCR reagent comprises the specificity forward primer (being GSP external source contrast-3) of described prostate cancer molecular marker miR-301a, the nucleotides sequence of this specificity forward primer is classified the sequence shown in SEQ ID NO.7 as, is 5 '-UUGAGCAACGCGAACAAAUCA-3 '.
In described diagnostic kit, serum total RNA extraction reagent comprises that nucleotides sequence classifies the external source contrast-1 of SEQ ID NO.2 as, is 5 '-CAACCTCCTAGAAA GA-3 '.
In described diagnostic kit, RNA adds polyA reagent and comprises that nucleotides sequence classifies the external source contrast-2 of SEQ ID NO.3 as, is 5 '-TGAGCAACGCGAACA A-3 '.
In described diagnostic kit, RT-PCR reagent comprises that sequence is the RT-primer of SEQ ID NO.4, be 5 '-CAGTGGTATCAACGCACTCCTTTTT TTTTTTTTTTTTTTTTTTTTTTTTTVN-3 ', wherein V is any in A, C and G, and N is any in A, T, C and G.
In described diagnostic kit, quantitative PCR reagent comprises that nucleotides sequence classifies the general reverse primer UPM-short-movie section of SEQ ID NO.5 as, is 5 '-CTCACAC GACTCACGACAC-3 '; Classifying the general reverse primer UPM-long segment of SEQ ID NO.6 as with nucleotides sequence, is 5 '-CTCACACGACTCACGACACC AGTGGTATCAACGCACTC-3 '.
Useful technique effect of the present invention is: the diagnosis that the present invention is prostate cancer provides a kind of new molecular marker miR-301a, and this molecular marker is applied to prepare in the diagnostic kit of diagnosing prostate cancer, the diagnostic kit diagnosing prostate cancer that uses this molecular marker and contain this molecular marker, simple to operate, draw materials conveniently, safety is without wound, and there is high specific, high sensitivity and the feature that is easy to a large amount of examinations, this molecular marker is particularly suitable for prostate cancer high risk population's screening, the evaluation of prostate cancer, the monitoring of prostate cancer therapy situation, the monitoring of prostate cancer direction of medication usage, with the field such as prostate cancer Prognosis scoveillance with in reagent.
Embodiment
For making the present invention easier to understand, below in conjunction with specific embodiment, further set forth the present invention, but following embodiment is only not used in and limits the scope of the invention for the present invention is described, in the following example, NM specific experiment method, carries out according to normal experiment method conventionally.
1. the extraction of total RNA in serum or blood plasma:
Extract each 2 milliliters of the blood that 3 prostate patients perform the operation first 7 days and perform the operation latter 7 days, extract simultaneously the same period each 2 milliliters of 3 normal human bloods in contrast.Centrifugal by carrying out after above-mentioned blood coagulation, finally get the centrifuge tube without DNA and RNA pollution that 1 milliliter of upper serum is placed in 1.5 milliliters.
Use RNA that Kang Wei ShiJi Co., Ltd produces to extract test kit and in above-mentioned serum, extract total RNA, in every 250 microlitre serum, add 1 microlitre external source contrast-1(Beijing Kuang Bosheng technology company limited to provide) monitor the extraction quality of RNA in above-mentioned serum.The total RNA extracting is by being used Therm NanoDrop 2000c instrument, the concentration determination that the ratio of mensuration 260/280nm ultraviolet wavelength carries out.The sequence of described external source contrast-1 is 5 '-CAACCTCCTAGAAAGA-3 ' (SEQ ID NO:2).
2. the microRNA in detection by quantitative serum:
1) add poly(A) tail:
In the PCR pipe (VWR company produces, 200 microlitres) without RNA enzyme, preparation adds the reaction solution of A tail, and system total amount is 20 microlitres.In every 20 microlitre system reaction solutions, add the special external source contrast-2(Beijing Kuang Bosheng technology company limited of 1 microlitre to provide) monitor tailing and the reverse transcription quality of miRNA, described reaction solution system is as shown in table 1.By the PCR pipe that configures reaction solution is housed, put into PCR instrument (Thermo), at 37 ℃, hatch 1 hour, obtain incubation reaction liquid I.The sequence of described external source contrast-2 is 5 '-TGAGCAACGCGAACAA-3 ' (SEQ ID NO:3).
Table 1
| Component | Add-on (microlitre) |
| External source contrast-2(20nm) | 1 |
| E.Coli polyA polymerase (takara company) | 0.5 |
| 10 times of polymerase solution of E.Coli polyA | 2 |
| Deoxidation gland sweet (10mm) | 2 |
| RNA | x |
| Ultrapure water without RNA and DNA pollution | 14-x |
| RNA enzyme inhibitors | 0.5 |
| Total amount | 20 |
In table, x represents that the RNA volume adding determined by the concentration of RNA, is x=500 nanogram/RNA concentration in this experiment.
2) RT-PCR obtains cDNA strand:
To through 1) add the RT-primer (Beijing Kuang Bosheng technology company limited provides) of 0.5 microlitre (0.5 nanogram/microlitre) in the reaction solution I that obtains after hatching, at 70 ℃, hatch 5 minutes, hatch and will hatch gained reaction solution II after end and put into immediately ice bath at least 2 minutes; Then according to becoming assignment system inverse transcription reaction liquid III shown in table 2; Gained inverse transcription reaction liquid III was hatched after 50 minutes at 50 ℃, at 70 ℃, be incubated 15 minutes, insulation is positioned over after finishing to be carried out coolingly in ice bath, obtain cDNA.After the cDNA obtaining can being diluted to the reverse transcription product that contains the total RNA of 1 nanogram in 1 microlitre system, carry out packing, be positioned over minus 20 degrees and preserve.The sequence of described RT-primer is 5 '-CAGTGGTATCAACGCACTCCTTTTTTTTT-7-TTTTTTTTTTTTTTTTTTTTTVN-3 ' (SEQ ID NO:4), and wherein V is any in A, C and G, and N is any in A, T, C and G.
Table 2
3) QPCR detection by quantitative:
At 2 milliliters of EP, manage in (production of VWR company) as table 3 dosage preparation reaction solution IV; After the reaction solution IV preparing is fully put upside down and mixed, be distributed in 96 holes point end PCR plates (production of VWR company) every Kong Zhongwei 18 microlitres; Use the volley of rifle fire (Gibson company, 1-10 microlitre) to adding specificity forward primer in above-mentioned hole, (be GSP external source contrast-3, by Beijing, Kuang Bosheng technology company limited provides), the sequence of this Auele Specific Primer is 5 '-UUGAGCAACGCGAACAAAUCA-3 ' (SEQ ID NO:7), and every hole is 2 microlitres; Then to adding respectively in above-mentioned hole after 10 microlitre paraffin oils with putting into ABI 7900PCR instrument after special-purpose pad pasting (VWR company) sealing, setting degree is as shown in table 4.
Table 3
The short-movie section of 10 * UPM-described in table 3 and 10 * UPM-long segment are general reverse primer, and wherein the nucleotides sequence of the general reverse primer of 10 * UPM-short-movie section is classified 5 '-CTCACACGACTCACGACAC-3 ' (SEQ ID NO:5) as; The nucleotides sequence of described 10 * UPM-long segment is classified 5 '-CTCACACGACTC ACGACACCAGTGGTATCAACGCACTC-3 ' (SEQ ID NO:6) as.
Table 4
3. adopt Array Tools 4.1.0 to carry out data analysis: with aforesaid method, can record target miRNA in sample serum and with reference to the Ct value of miRNA, according to the Ct value level of reference, try to achieve the relative content of target miRNA in serum.With aforesaid method can record that prostate cancer is preoperative, the average delta Ct value of miR-301a is respectively 11.2,4.10 and 3.53 in postoperative 7 days of prostate cancer and each sample Peripheral Blood of normal control, result shows that the relative content of miR-301a in prostate cancer peripheral blood increases than Normal group is obvious, within postoperative 7 days, is substantially returned to normal value level.Single factor Cox risk regression analysis and the demonstration of K-M survival analysis, miR-301a can be used as the biomarker that development occurs in prostate cancer.
4. the standardization of data:
The Ct value of the external source of take contrast-1 is reference, tries to achieve the relative content of miRNA in serum, and result shows that miR-301a relative content in serum before operation in patients significantly raises, and operative results is to normal level.With 2 of classics in qPCR detection
-Δ Ctmode represent the level (Δ Ct is that target miRNA contrasts the poor of-1 Ct value with external source) of object miRNA in serum.
5. the horizontal diagnosing prostate cancer of object miRNA in serum:
Compare with the low levels of miR-301a in normal control serum, in the preoperative serum of patients with prostate cancer, the level of miR-301a raises more than 5 times, and difference has statistical significance; Statistical study shows after operation in patients in serum that miR-301a content is compared difference not statistically significant with normal control.
Sequence table
Bo Taian bio tech ltd, <110> Suzhou
<120> prostate cancer molecular marker miR-301a and application thereof
<130> 2012
<160> 7
<170> PatentIn version 3.5
<210> 1
<211> 22
<212> RNA
<213> Homo sapiens
<400> 1
gcucugacuu uauugcacua cu 22
<210> 2
<211> 16
<212> DNA
<213> artificial sequence
<400> 2
caacctccta gaaaga 16
<210> 3
<211> 16
<212> DNA
<213> artificial sequence
<400> 3
tgagcaacgc gaacaa 16
<210> 4
<211> 52
<212> DNA
<213> artificial sequence
<220>
<221> misc_feature
<222> (52)..(52)
<223> n is a, c, g, or t
<400> 4
cagtggtatc aacgcactcc tttttttttt tttttttttt tttttttttt vn 52
<210> 5
<211> 19
<212> DNA
<213> artificial sequence
<400> 5
ctcacacgac tcacgacac 19
<210> 6
<211> 38
<212> DNA
<213> artificial sequence
<400> 6
ctcacacgac tcacgacacc agtggtatca acgcactc 38
<210> 7
<211> 21
<212> DNA
<213> artificial sequence
<400> 7
uugagcaacg cgaacaaauc a 21
Claims (10)
1. a prostate cancer molecular marker miR-301a, is characterized in that: the nucleotides sequence of described prostate cancer molecular marker miR-301a is classified the sequence shown in SEQ ID NO.1 as.
2. the application of prostate cancer molecular marker miR-301a according to claim 1 in preparing diagnosing prostate cancer reagent.
3. the application of prostate cancer molecular marker miR-301a according to claim 2 in preparing diagnosing prostate cancer reagent, it is characterized in that: described diagnosing prostate cancer reagent passes through to detect the content of miR-301a in subject's serum, and this miR-301a content is compared diagnosing prostate cancer with normal level miR-301a content.
4. the application of prostate cancer molecular marker miR-301a according to claim 3 in preparing diagnosing prostate cancer reagent, is characterized in that: in described subject's serum, the content of miR-301a detects by quantifying PCR method.
5. the application of prostate cancer molecular marker miR-301a according to claim 2 in preparing diagnosing prostate cancer reagent, is characterized in that: described prostate cancer molecular marker miR-301a is for the preparation of the diagnostic kit of diagnosing prostate cancer.
6. a diagnostic kit for diagnosing prostate cancer claimed in claim 5, is characterized in that: described diagnostic kit comprises:
(1) serum total RNA extraction reagent,
(2) RNA adds polyA reagent,
(3) RT-PCR reagent,
(4) quantitative PCR reagent;
Wherein said quantitative PCR reagent comprises the specificity forward primer of described prostate cancer molecular marker miR-301a, and the nucleotides sequence of this specificity forward primer is classified the sequence shown in SEQ ID NO.7 as.
7. the diagnostic kit of diagnosing prostate cancer according to claim 6, is characterized in that: in described diagnostic kit, serum total RNA extraction reagent comprises that nucleotides sequence classifies the external source contrast-1 of SEQ ID NO.2 as.
8. the diagnostic kit of diagnosing prostate cancer according to claim 6, is characterized in that: in described diagnostic kit, RNA adds polyA reagent and comprises that nucleotides sequence classifies the external source contrast-2 of SEQ ID NO.3 as.
9. the diagnostic kit of diagnosing prostate cancer according to claim 6, is characterized in that: in described diagnostic kit, RT-PCR reagent comprises that sequence is the RT-primer of SEQ ID NO.4.
10. the diagnostic kit of diagnosing prostate cancer according to claim 6, it is characterized in that: in described diagnostic kit, quantitative PCR reagent comprises that nucleotides sequence classifies the general reverse primer UPM-short-movie section of SEQ ID NO.5 as, and nucleotides sequence is classified the general reverse primer UPM-long segment of SEQ ID NO.6 as.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210314263.0A CN103667281A (en) | 2012-08-30 | 2012-08-30 | Molecular marker miR-301a for prostatic cancer and application of molecular marker miR-301a |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210314263.0A CN103667281A (en) | 2012-08-30 | 2012-08-30 | Molecular marker miR-301a for prostatic cancer and application of molecular marker miR-301a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103667281A true CN103667281A (en) | 2014-03-26 |
Family
ID=50306054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210314263.0A Pending CN103667281A (en) | 2012-08-30 | 2012-08-30 | Molecular marker miR-301a for prostatic cancer and application of molecular marker miR-301a |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103667281A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120107825A1 (en) * | 2010-11-01 | 2012-05-03 | Winger Edward E | Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna |
-
2012
- 2012-08-30 CN CN201210314263.0A patent/CN103667281A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120107825A1 (en) * | 2010-11-01 | 2012-05-03 | Winger Edward E | Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna |
Non-Patent Citations (3)
| Title |
|---|
| CAN LIU: "MicroRNA Regulation of Prostate Cancer Stem/Progenitor Cells and Prostate Cancer Development", 《TEXAS MEDICAL CENTER LIBRARY》 * |
| NING-YI SHAO ET AL: "comprehensive survey of human brain microRNA by deep sequencing", 《BMC GENOMICS》 * |
| NING-YI SHAO ET AL: "comprehensive survey of human brain microRNA by deep sequencing", 《BMC GENOMICS》, vol. 11, no. 409, 31 December 2010 (2010-12-31), pages 2 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105018594B (en) | A kind of colorectal cancer early diagnosis marker and related kit | |
| CN119220676A (en) | Prostate cancer detection kit or device and detection method | |
| CN102876676A (en) | Blood serum/blood plasma micro ribonucleic acid (miRNA) marker relevant with pancreatic cancer and application thereof | |
| Cicatiello et al. | Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis | |
| Zhang et al. | Up‐regulation of plasma lncRNA CACS15 distinguished early‐stage oral squamous cell carcinoma patient | |
| CN105603101A (en) | Application of system for detecting expression quantity of eight miRNAs in preparation of product for diagnosing or assisting in diagnosing hepatocellular carcinoma | |
| CN104450893A (en) | Probe group and gene chip for detecting bladder cancers | |
| Rao et al. | Identification of plasma exosomes long non-coding RNA HAGLR and circulating tumor cells as potential prognosis biomarkers in non-small cell lung cancer | |
| CN106967719B (en) | Application of a long non-coding RNA as a molecular marker for prostate cancer | |
| CN104694623A (en) | Plasma miRNA marker for diagnosis of lung cancer and application | |
| CN107519193A (en) | Esophageal squamous cell carcinoma early molecule diagnosis marker and its application | |
| CN103074431B (en) | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum | |
| CN103205423A (en) | Prostate cancer biomarker miR-126-5P, diagnostic kit and application | |
| CN105219841A (en) | The detection kit of a kind of lung cancer differential expression microRNA and application thereof | |
| CN114150063B (en) | Urine miRNA marker for bladder cancer diagnosis, diagnosis reagent and kit | |
| TWI571514B (en) | Method for accessing the risk of having colorectal cancer | |
| WO2021159562A1 (en) | Circulating mirna and carcino-embryonic mirna marker related to pan-tumor auxiliary diagnosis, and use thereof | |
| CN106319062A (en) | Minimally invasive kit for assistant diagnosis or efficacy prediction of efficacy prediction | |
| CN106636334B (en) | MicroRNA marker group and application thereof in preparation of lymph node metastasis kit for detecting gastric cancer | |
| CN108753980A (en) | A screening kit for metastatic screening of papillary thyroid microcarcinoma | |
| Torres et al. | Knowledge and expectations about miRNAs as biomarkers in head and neck squamous cell cancers | |
| CN103667282A (en) | Molecular marker miR-628-3P for prostatic cancer and application of molecular marker miR-628-3P | |
| CN103627704A (en) | Prostatic cancer molecular marker miR-19a and applications thereof | |
| CN116377074A (en) | Application of miR-15a-5p in early diagnosis and prognosis evaluation of oral squamous cell carcinoma | |
| CN103361415A (en) | Prostate cancer biomarker miR-379 and diagnostic kit as well as application of prostate cancer biomarker miR-379 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140326 |